A snipit from The Australian newspaper today..
" biotech Daily sage Mark Sinatra etmates the testosterone replacement market could be worth US 1.4 - 1.6bn by 2012, a year after Axiron's planned launch. Assuming 10% market share and a 20% royalty rate, this equates to $US 28- 32Mil. If Axiron grabs a 50% share, this rises to $US140- $US160mil.
We had Acrux as a long term buy at $2.42 in March. Given the time lag involved in royalties flowing, we suggest myopic investors take profits. Otherwise it's a HOLD.
The full take on this story is on today's Australian paper by Tim Boreham.
DYOR
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $6.524M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.7¢ | 1.5¢ | $19.90K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 463664 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 320000 | 2 |
View Market Depth
| Last trade - 15.56pm 25/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |